Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis
Authors:
- 27 October 2020
- journal article
- review article
- Published by Taylor & Francis in Drug and Chemical Toxicology
- Vol. 45 (4) , 1443-1448
Abstract
Prolonged survival and expanded treatment options in myeloma patients have led to adverse events associated with treatment getting increased attention. This systematic review and meta-analysis aimed to determine the incidence of ixazomib-associated cardiovascular adverse events (CVAEs) and to compare the rates of ixazomib-associated CVAEs and related therapies. CVAEs were defined as heart failure, hypertension, ischemia, and arrhythmia. All-grade and high-grade CVAEs and study characteristics were recorded. A total of 266 potentially relevant articles were identified, and 246 were excluded after review. Twenty studies of 1715 patients with multiple myeloma were thus considered in this study. The estimated rates of all-grade and high-grade ixazomib associated CVAEs were 11.2 and 3.7%, respectively. Subgroup analysis showed that median age ≥65 years, none phase 1 trial and combination regimen were associated with higher rates of high-grade ixazomib associated CVAEs. Ixazomib was association with increased high-grade CVAEs risk (RR = 1.679, 95% CI: 1.078-2.615, P = 0.022). Ixazomib was associated with a significant rate of high-grade CVAEs. Future studies are needed to identify patients at high risk for high-grade CVAEs.Keywords
This publication has 36 references indexed in Scilit:
- Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialThe Lancet, 2019
- All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaEuropean Journal of Cancer, 2019
- Clinical Pharmacology of Ixazomib: The First Oral Proteasome InhibitorClinical Pharmacokinetics, 2018
- Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic AnalysisThe Journal of Clinical Pharmacology, 2017
- Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and CarfilzomibCardiovascular Toxicology, 2016
- The Effect of a High‐Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or LymphomaThe Journal of Clinical Pharmacology, 2016
- Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 studyJournal of Hematology & Oncology, 2015
- Primary Proteasome Inhibition Results in Cardiac DysfunctionEuropean Journal of Heart Failure, 2013
- In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma CellsClinical Cancer Research, 2011
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986